alta ii: brigatinib in crizotinib-resistant alk nsclc
Published 5 years ago • 182 plays • Length 4:38Download video MP4
Download video MP3
Similar videos
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
2:09
alta-1l: brigatinib vs crizotinib in alk ansclc
-
6:58
alta-1l: brigatinib versus crizotinib for alk nsclc
-
2:13
alk nsclc: brigatinib indication and alta trial
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
4:00
alta-1l: final overall survival results of brigatinib vs crizotinib for alk lung cancer
-
1:21
alta-1l: brigatinib vs crizotinib
-
2:18
alta-1l: brigatinib is superior to crizotinib in alk nsclc
-
4:10
crizotinib resistance in alk nsclc
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
5:51
alta-1l: brigatinib vs crizotinib for alk advanced non small cell lung cancer patients
-
1:14
dr. rotow on first-line brigatinib versus crizotinib in alk nsclc
-
4:37
fda approval of brigatinib for alk nsclc
-
1:38
dr. drilon on the safety profile of brigatinib in alk nsclc
-
1:34
dr. pennell on the use of brigatinib in alk nsclc
-
0:52
dr. rotow on remaining questions with brigatinib in alk nsclc
-
4:28
brigatinib for nsclc, latest research and overcoming complications
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc